Incyte Enters Pricing Agreement with CMS for Jakafi in State Medicaid Programs

Incyte Corporation has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (CMS) to align the pricing of its drugs Jakafi and Jakafi XR for state Medicaid programs with international markets.

Key Details

• Pricing Alignment: State Medicaid programs will gain access to Jakafi and Jakafi XR at prices consistent with those in a defined group of other advanced, industrialized nations.
• Regulatory Exemption: In exchange, Incyte expects it will not be subject to certain future CMS pricing mandates, specifically mentioning the proposed GUARD and GLOBE models.
• Financial Impact: The company does not expect the agreement to affect its 2026 financial guidance or have a material impact on its future financial outlook.